Open Monoclonal Technology Inc. (OMT) has licensed its proprietary OmniRat, OmniMouse and OmniFlic human antibody generation platforms to Five Prime Therapeutics Inc., making it OMT’s 16th corporate partner globally with such multi-platform access.

“Five Prime’s large collection of medically relevant extracellular proteins combined with its sophisticated screening technology is particularly well suited for the identification of therapeutic human antibody targets,” said Roland Buelow, OMT’s founder and chief executive officer. “We are pleased to grant Five Prime access to OMT’s mono- and bi-specific antibody platforms and deep antibody repertoire sequencing technology for the generation of novel therapeutic candidates.”

OMT is a leader in genetic engineering of animals for the generation of human therapeutic antibodies, naturally optimized human antibodies, and the only company in the world with four transgenic animal platforms, jointly known as OmniAb.

All four OmniAb platforms deliver human antibodies with high affinity, specificity, expression, solubility and stability. They use patented technology, have broad freedom to operate and are available worldwide for all targets and indications.

Current partners include Amgen, Caltech, Celgene, Chugai, Five Prime, Genmab, Genentech, Gloria Pharmaceuticals, HanAll, Janssen, Merck KGaA, Pfizer, Roche, Symphogen, University of Nottingham and several undisclosed biotech and pharmaceutical companies. Animal hosting and OmniAb antibody discovery services are available via Antibody Solutions and Sage Labs in the U.S., Aldevron and Taconic Biosciences in Europe, and WuXi AppTec in China.